B+
Bull case
25%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
SPRY
ARSBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Neffy has early commercial traction, with Q1 U.S. product revenue of $17.5 million, prescription volume reportedly tripling year over year, approximately 90% commercial coverage, and 57% of covered lives without prior authorization.
Posture
Constructive
Lead driver
Sentiment
What changed
2 setup hits (3d) with net bullish as of 2026-09-09.
What can break
An officer reported an open-market sale of 25,000 shares at $10 on June 12; this is a secondary sentiment signal, not operating evidence. [#SEC-FORM4-2026-06-12]
Momentum
4
Value
41
Sentiment
89
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $6.25 · Bull $9.50 · Bear $3.25Analysis 2026-08-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $23.50
Why
Momentum4 · Δ7d +0.4
Value41 · Δ7d 0.0
Sentiment89 · Δ7d +16.6
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 2 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +16.6.
Contradictions & invalidation
- • An officer reported an open-market sale of 25,000 shares at $10 on June 12; this is a secondary sentiment signal, not operating evidence. [#SEC-FORM4-2026-06-12]
- • High SG&A, operating losses, and cash burn increase execution and financing sensitivity. [#SEC-8K-2026-05-15]
- • The missed July commercial coverage inflection weakens the original payer-driven rerating thesis.
Catalyst clock
2026-09-01
Payer-access disappointment remains the near-term overhang
Lead driver: Sentiment · See AI snapshot
Momentum
4
9% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.6
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
89
62% active weight
Current posture
7d trendImproving
Δ7d
+16.6
Δ21d
+23.6
Why this grade
Composite grade B. Momentum 3.7 / Value 41.2 / Sentiment 89.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-04. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$6.25
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$620.55M
Beta
0.79
Shares Out
99.45M
P/E (TTM) · Derived
-3.6
P/S (TTM)
7.60
P/FCF (TTM)
83.51
Rev YoY
+114.2%
EPS YoY
+37.6%
Gross Margin
+71.4%
Op Margin
-185.0%
Net Debt
-$148.02M
Current Ratio
3.48
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data